이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management (COMPARE)

2026년 11월 10일 업데이트: Jessica McAlpine, British Columbia Cancer Agency

Co-Existent Endometrial and Ovarian Carcinoma: Optimization of Treatment Through Molecular and Pathological Refinement

Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery.

The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment.

To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery.

Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

PURPOSE: To determine the safety of de-escalated/optimized adjuvant treatment of patients with CEOC directed by tumor molecular status and strictly defined pathology criteria.

HYPOTHESIS: Molecular classification in combination with carefully selected and restricted pathological features will identify a subset of patients with CEOCs who are at very low risk of disease recurrence and are candidates for de-escalated/optimized adjuvant therapy.

JUSTIFICATION: CEOC patients are often given chemotherapy +/- pelvic radiation, despite unclear benefit and substantial toxicity from short and long termshort- and long-term treatment-related side effects, such as neuropathy, fatigue and cognitive issues. Overtreatment also results in financial challenges for patients from loss of income, travel expenses related to many appointments and delayed return to work. Although the World Health Organization created a new substage within the endometrial cancer staging system to support the delivery of less (or no) treatment for CEOC patients based on pathology criteria that supports favourable outcomes, studies have shown that molecular features of endometrial cancer can also be used to identify a subset of CEOC patients at very low risk of recurrence who can be directed to treatment de-escalation. In order to further evaluate these findings and change clinical practice, a prospective trial is needed to assess the safety of de-escalated treatment for CEOC patients.

RESEARCH DESIGN: This is a phase II, prospective, multi-centre, trial where pathologic and molecular features will be used to identify patients who can be offered de-escalated therapy. Molecular classification- assessing immunohistochemistry for MMR, p53, and ER status in the endometrium and ovarian tumors will be performed. Next generation sequencing for POLE mutation status is needed at least in the endometrial sample. Molecular criteria to define low risk CEOCs will include POLEmut, ER strong + NSMP, and MSH2/MSH6 or PMS2 loss (MMRd without MLH1 promoter hypermethylation) and provided pathologic criteria are also met would enable patients to be considered for de-escalation. Intermediate and high risk carcinomas, encompassing MLH1 promoter methylated, ER-negative NSMP and p53abn CEOCs would not be enrolled.

The first site will open in BC, Canada. Due to this rare patient population, other high-volume national and international centers will be sought. Collaborating centers will be selected based on access to molecular testing and interest in providing their CEOC patients with the opportunity to participate in this trial.

The aim of this trial is to assess the safety of de-escalated adjuvant treatment in CEOC patients. Patients that fit the eligibility criteria will have the option of choosing to receive treatment de-escalation (no chemotherapy or radiation) vs. additional treatment (chemotherapy +/- radiation) following their primary staging surgery.

Recruitment will take place over 3 years from November 1, 2026 - November 1, 2029. Participants will be followed for 3 years after their enrollment after surgery.

Baseline Measures:

  1. Imaging: If a patient has not had imaging performed on their chest, abdomen and pelvis within 60 days prior to trial enrollment, the patient's gynecologic oncologist will order this imaging to be done within five weeks after trial enrollment. Accepted imaging modalities are (CT, chest x-ray, MRI, PET). Note that imaging prior to surgery is standard of care.
  2. Questionnaires: Upon signing the consent form (baseline), patients will be prompted to complete 3 questionnaires about their quality of life and their thoughts regarding their treatment decision (active surveillance vs. additional treatment):

1. EORTC QLQ-30 2. FCRI-SF 3. EQ-5D-5L

These questionnaires will be administered through an online platform for the participant to complete on their own device or on a tablet/laptop provided by the study team. Physical copies will be made available upon patient request.

If patient's do not speak English or feel comfortable completing the questionnaires in English, the study coordinator will attempt to obtain these questionnaires in the patient's preferred language.

Follow-Up Measures:

  1. Imaging: Imaging of the patient's chest, abdomen, and pelvis will be ordered 36 months after enrollment. Although the exact timepoints after surgery are up to the doctor's discretion, additional imaging post-surgery is a part of a patient's standard of care.
  2. Questionnaires: Patients will complete the three questionnaires listed above at enrollment, 4, 12, 24, & 36 months after enrollment. These questionnaires will be administered at patients follow-up appts or through an online platform.
  3. Symptom History & Physical exam: It is standard of care to review patient symptoms and perform abdominal and pelvic examinations during their follow-up appts. This will be recorded by the patient's oncologist within their clinical note. The local study coordinator will review the clinic note and record the outcomes of this symptom review and physical exam within that patient's record on the data collection platform.

Recurrence:

If a patient's cancer recurs within the 3 year follow-up period, patients will undergo the following study procedures annually from the date of recurrence:

  1. Two questionnaires (EORTC QLQ-30 & EQ-5D-5L)
  2. Symptom History & Physical exam

STATISTICAL ANALYSIS: Assuming 68 patients with molecularly stratified CEOC (exclusion of exclusion of MMRd with MLH1 immunohistochemistry loss or MLH1 promoter hypermethylation, p53abn and NSMP ER negative-low) are accrued over 3 years and followed for 3 years, the total person-years of follow-up would be 306 and the upper 95% confidence limit for the true 3-year pelvic recurrence rate would be 7% when the observed 3-year pelvic recurrence rate is 4% from CEOCs in this cohort. Therefore, a true 3-year pelvic recurrence rate of 7%, which for this trial is considered unacceptably high, can be ruled out with 95% confidence in this cohort. Allowing that ~5% of patients may be lost to follow up and 25% of patients may not elect to undergo de-escalated therapy (e.g., will be treated, not counting towards n=68), we estimate needing to enroll ~90 patients to yield 68 evaluable receiving de-escalation. As the statistical analysis has been designed to demonstrate the safety of de-escalation within the group of patients that received no additional treatment, patients who receive adjuvant treatment following surgery are not part of this trial's statistical analysis.

연구 유형

중재적

등록 (추정된)

90

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
        • British Columbia Cancer Agency - Vancouver
        • 연락하다:
        • 수석 연구원:
          • Amy Jamieson

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Had primary surgery consisting of hysterectomy (any surgical approach) and bilateral salpingo-oophorectomy.
  • Lymph node dissection can be performed as per institutional practice (sentinel node biopsy or full).
  • Had no macroscopic residual disease after surgery.

Meet the molecular and pathological criteria (1, 2, or 3) as determined or identified by their local oncologist and pathologist:

  1. (Molecular) NSMP ER strong positive:

    1. Endometrial site

      • Low grade endometrioid (grade 1-2)
      • <50% myometrial invasion (FIGO 2009 stage IA)
      • Absence of substantial lymphovascular invasion (LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2)
  2. (Molecular) POLEmut

    1. Endometrial site

      • FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2),
  3. (Molecular) MSH2, MSH6, or PMS2 loss (MMRd without MLH1 promoter hypermethylation)

    1. Endometrial site

      • FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI)
    2. Ovarian site

      • Low grade endometrioid (grade 1-2)

        • bilateral (stage IB),
        • intraoperative spill (stage ICI),
        • preoperative rupture (stage IC2),
        • surface involvement (stage IC2),

Exclusion Criteria:

  • Individuals with MMRd MLH1 promoter hypermethylation or p53abn status in their ovarian or endometrial tumour.
  • Individuals with ER negative-low status in the endometrium.
  • Individuals with any additional sites of metastases.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment De-escalation

After undergoing surgery, patients elect to not receive any further treatment (such as radiation or chemotherapy) to treat their cancer. Instead their condition will be closely followed by their oncologist for 3 years.

Receiving no further treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.

다른 이름들:
  • 적극적인 감시
다른: Additional Treatment

After undergoing surgery, patients elect to receive additional treatment (such as radiation or chemotherapy) to treat their cancer. The type of additional treatment received will be determined by the patient's oncologists in conjunction with the patient. These patients will be closely followed by their oncologist for 3 years.

Receive additional treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.

다른 이름들:
  • Adjuvant treatment
  • Additional post-surgical treatment

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pelvic recurrence rate of participants in the treatment de-escalation group
기간: Enrollment to 3 years

The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer in their pelvis within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.

Enrollment to 3 years

2차 결과 측정

결과 측정
측정값 설명
기간
The rate of isolated vaginal recurrence and distant metastases.
기간: Enrollment to 3 years

The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer within their vagina and/or developed distant metastases within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.

Enrollment to 3 years
Recurrence-free survival (RFS)
기간: Date of surgery to 3 years after study enrollment

Recurrence-free survival is defined as the time from surgery/staging until CEOC disease recurrence.

This measure will be obtained through clinical follow-up e.g., symptom review & physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

Date of surgery to 3 years after study enrollment
Worries about cancer recurrence
기간: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

The Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) will be administered to patients to understand their level of worry/fear they have about their cancer recurring over the past month. On the FCRI-SF, a lower score represents little fear or worry of a recurrence whereas a higher score represents greater fear or worry of a recurrence.

At enrollment, then at 4, 12, 24, and 36 months after enrollment.
Health economic impact of patients' post-surgery treatment decision
기간: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

The EuroQol EQ-5D-5L questionnaire will be administered to patients to obtain their health related utility scores to understand the health economic impact of treatment de-escalation compared to receiving additional adjuvant treatment. Patients will indicate their health status on a scale from 0 (worst health status) to 100 (best health status).

At enrollment, then at 4, 12, 24, and 36 months after enrollment.
Disease specific survival (DSS)
기간: Date of surgery to 3 years after study enrollment

Disease specific survival is defined as the time from surgery/staging until death from CEOC disease.

This measure will be obtained through clinical follow-up e.g., symptom review & physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

Date of surgery to 3 years after study enrollment
Overall survival (OS)
기간: Date of surgery to 3 years after study enrollment

Overall survival is the time from surgery/staging until death from any cause (including death from CEOC disease or death from other non-cancer related causes).

This measure will be obtained through clinical follow-up e.g., symptom review & physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.

Date of surgery to 3 years after study enrollment
Health-related quality of life
기간: At enrollment, then at 4, 12, 24, and 36 months after enrollment.

The 30-item EORTC QLG Core Questionnaire (EORTC QLQ-C30) will be administered to patients to measure their quality of life throughout the trial. This questionnaire contains different scales to evaluate patients' function, symptoms, and global health status. Raw scores from the questionnaire are converted to a standardized scale from 0 - 100, with a higher score for the function and global health status scales representing a better level of functioning and a higher score for the symptom scale representing a higher level of symptoms experienced.

At enrollment, then at 4, 12, 24, and 36 months after enrollment.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jessica McAlpine, British Columbia Cancer Agency
  • 수석 연구원: Amy Jamieson, British Columbia Cancer Agency

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 30일

기본 완료 (추정된)

2032년 10월 30일

연구 완료 (추정된)

2032년 10월 30일

연구 등록 날짜

최초 제출

2026년 9월 2일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • COMPARE H26-00976

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Other researchers can request data from the PI's (McAlpine and Jamieson) directly

IPD 공유 기간

From study start to 5 years from study completion, estimated.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .